Janus Henderson Group PLC decreased its position in West Pharmaceutical Services, Inc. (NYSE:WST – Free Report) by 17.0% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 8,172 shares of the medical instruments supplier’s stock after selling 1,669 shares during the quarter. Janus Henderson Group PLC’s holdings in West Pharmaceutical Services were worth $2,050,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently bought and sold shares of the company. State Street Corp grew its stake in shares of West Pharmaceutical Services by 2.1% in the 2nd quarter. State Street Corp now owns 3,271,866 shares of the medical instruments supplier’s stock worth $715,884,000 after purchasing an additional 68,330 shares during the last quarter. Artisan Partners Limited Partnership increased its holdings in shares of West Pharmaceutical Services by 2.9% in the fourth quarter. Artisan Partners Limited Partnership now owns 2,850,401 shares of the medical instruments supplier’s stock valued at $784,259,000 after buying an additional 79,481 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of West Pharmaceutical Services by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 1,869,086 shares of the medical instruments supplier’s stock valued at $512,250,000 after acquiring an additional 11,962 shares during the last quarter. Generation Investment Management LLP boosted its stake in shares of West Pharmaceutical Services by 60.0% during the 4th quarter. Generation Investment Management LLP now owns 1,561,869 shares of the medical instruments supplier’s stock worth $429,733,000 after acquiring an additional 585,855 shares in the last quarter. Finally, Morgan Stanley grew its holdings in shares of West Pharmaceutical Services by 3.6% in the 4th quarter. Morgan Stanley now owns 1,531,858 shares of the medical instruments supplier’s stock worth $421,476,000 after acquiring an additional 53,229 shares during the last quarter. 93.90% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
Several research firms have issued reports on WST. Barclays upgraded West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $310.00 to $400.00 in a report on Tuesday, June 9th. TD Cowen reissued a “buy” rating on shares of West Pharmaceutical Services in a research report on Wednesday, July 15th. Morgan Stanley lifted their target price on shares of West Pharmaceutical Services from $325.00 to $365.00 and gave the company an “equal weight” rating in a research note on Thursday, July 9th. Citigroup upped their price objective on shares of West Pharmaceutical Services from $400.00 to $412.00 and gave the stock a “buy” rating in a report on Monday, August 3rd. Finally, Wolfe Research assumed coverage on shares of West Pharmaceutical Services in a research report on Monday, June 1st. They set an “outperform” rating and a $375.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $368.08.
West Pharmaceutical Services Price Performance
Shares of West Pharmaceutical Services stock opened at $353.61 on Friday. West Pharmaceutical Services, Inc. has a 1-year low of $223.83 and a 1-year high of $386.00. The firm has a fifty day simple moving average of $342.97 and a 200-day simple moving average of $292.25. The company has a current ratio of 2.82, a quick ratio of 2.12 and a debt-to-equity ratio of 0.07. The stock has a market capitalization of $24.89 billion, a price-to-earnings ratio of 45.28, a PEG ratio of 2.47 and a beta of 1.15.
West Pharmaceutical Services (NYSE:WST – Get Free Report) last announced its earnings results on Thursday, July 23rd. The medical instruments supplier reported $2.37 EPS for the quarter, topping the consensus estimate of $2.08 by $0.29. The firm had revenue of $872.30 million for the quarter, compared to the consensus estimate of $839.98 million. West Pharmaceutical Services had a net margin of 16.98% and a return on equity of 20.11%. The business’s quarterly revenue was up 13.8% on a year-over-year basis. During the same quarter last year, the firm posted $1.84 EPS. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. On average, sell-side analysts expect that West Pharmaceutical Services, Inc. will post 8.94 earnings per share for the current year.
West Pharmaceutical Services Dividend Announcement
The firm also recently declared a quarterly dividend, which was paid on Wednesday, August 5th. Shareholders of record on Wednesday, July 29th were given a $0.22 dividend. This represents a $0.88 annualized dividend and a yield of 0.2%. The ex-dividend date of this dividend was Wednesday, July 29th. West Pharmaceutical Services’s payout ratio is currently 11.27%.
About West Pharmaceutical Services
West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.
In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.
Read More
- Five stocks we like better than West Pharmaceutical Services
- Quantum Earnings Week: Winners and Losers Are Finally Emerging
- Axon’s Post-Earnings Pullback May Be More About Valuation Than Growth
- Uber Stock Lags in 2026, But Cash Flow and AV Bets Fuel Upside
- AppLovin Stock Hits 52-Week Low as Analysts Trim Targets, Stay Bullish
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.
